Acutaas Chemicals Ltd (NSE: ACUTAAS) and Wockhardt Ltd (NSE: WOCKPHARMA) are both listed in the Medicinal Chemicals and Botanical Products industry. Acutaas Chemicals has a market capitalisation of ₹31,869 Cr and Wockhardt ₹30,817 Cr, as of 9 Nov 2026. Their P/E ratios are 89.8 and 144.8 respectively. Return on equity is 23.52% for Acutaas Chemicals and 4.00% for Wockhardt. Over one year, Acutaas Chemicals's share price is up 113.6% and Wockhardt's is up 43.7%.
| Metric | Acutaas Chemicals | Wockhardt |
|---|---|---|
| NSE Symbol | ACUTAAS | WOCKPHARMA |
| BSE Code | 543349 | 532300 |
| Share Price | ₹3,866.60 | ₹2,031.50 |
| Market Cap | ₹31,869 Cr | ₹30,817 Cr |
| P/E Ratio | 89.8 | 144.8 |
| Return on Equity | 23.52% | 4.00% |
| Return on Assets | 15.74% | 3.67% |
| Dividend Yield | 0.06% | 0.00% |
| Beta (1Y) | 0.23 | 1.03 |
| 1-Year Price Change | +113.6% | +43.7% |
| 3-Month Price Change | +17.8% | +5.2% |
| 52-Week Range | ₹1,570.00 – ₹4,045.30 | ₹1,086.70 – ₹2,422.30 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹437 Cr | ₹969 Cr |
| Quarterly Net Profit | ₹123 Cr | ₹73 Cr |
| Net Margin | 28.2% | 7.5% |
| EPS (Basic, Quarter) | ₹15.29 | ₹4.85 |
| Results Basis | consolidated | consolidated |
| Headquarters | Surat, Gujarat | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson’s, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist chemicals to semiconductor applications; electrol…
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafith…
Acutaas Chemicals has a market capitalisation of ₹31,869 Cr, against ₹30,817 Cr for Wockhardt as of 9 Nov 2026, so the two are about the same size by market cap.
Acutaas Chemicals has a P/E of 89.8 and Wockhardt a P/E of 144.8 as of 9 Nov 2026.
Acutaas Chemicals has a return on equity of 23.52% and Wockhardt 4.00%.
Acutaas Chemicals's share price is up 113.6% over one year and Wockhardt's is up 43.7%.
Acutaas Chemicals reported revenue of ₹437 Cr and net profit of ₹123 Cr for Q2 FY27. Wockhardt reported revenue of ₹969 Cr and net profit of ₹73 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.